Bio-Rad Laboratories (BIO)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
Research Workspace
Put BIO beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Non-GAAP operating margin between 10.0% and 12.0% in fiscal 2026: Q2 FY26 op margin 11.2% vs 10-12% target; FY26 guide 10-12%.
View ThesisRevenue is growing steadily — about 1% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 22%.
View QualityManagement screens strong on capital allocation, margins, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 15% growth a year, above the roughly 2% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskBIO's growth relies on achieving non-GAAP, currency-neutral revenue growth of -3% to 0.5%. Recent earnings showed a beat, with Q2 FY26 EPS at 2.62, exceeding expectations by 12%. It trades at 42× P/E versus a peer median of 34×, indicating the market prices in more growth than forecasted. The primary risk is the potential for guidance cuts, with a 24% probability of missing next-quarter estimates. Peer multiples imply a price about 15% below where it trades, suggesting it looks expensive on this basis. Our read is provisional.
Trailing returns as of 2026-09-04. BIO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering BIO (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare BIO with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BIO Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put BIO next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Achieve non-GAAP, currency-neutral revenue growth of -3.0% to 0.5%
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Aligns with revenue growth and cost savings objectives.

Threatens: Achieve revenue growth of -3.0% to 0.5%
Cautious outlook raises concerns about future growth.

Activist involvement suggests potential for improved operational efficiency.